1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Skelton, N.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 42 9324 9334 10.1021/bi034386c 12899619 Complex with a Phage Display-Derived Peptide Provides Insight into the Function of Insulin-like Growth Factor I 2003 UK Chem.Biol. CBOLE2 2050 1074-5521 9 495 506 10.1016/S1074-5521(02)00129-1 Rapid Identification of Small Binding Motifs with High-Throughput Phage Display. Discovery of Peptidic Antagonists of Igf-1 Function 2002 10.2210/pdb1pmx/pdb pdb_00001pmx 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 7663.752 Insulin-like growth factor IB 1 man polymer 1879.216 IGF-1 ANTAGONIST F1-1 1 syn polymer IGF-IB, Somatomedin C no no GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA A polypeptide(L) no no RNCFESVAALRRCMYG RNCFESVAALRRCMYG B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia sample 9606 Homo sapiens 562 Escherichia coli 43E7 plasmid PBKIGF2B database_2 pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2003-10-21 1 1 2008-04-29 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name structure of free peptide igf-f1-1 RCSB Y RCSB 2003-06-11 REL SEQUENCE DERIVED FROM PHAGE DISPLAY LIBRARY AND PREPARED BY CHEMICAL SYNTHESIS sample THE RESONANCE ASSIGNMENTS WERE DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY. LEAST VIOLATION OF EXPERIMENTAL RESTRAINTS 100 20 3D_15N-SEPARATED_NOESY HNHA D-HNHB 3D 15N-SEPARATED LOW MIXING TIME TOCSY 2D-15N-FILTERED NOESY 3D_13C-SEPARATED_NOESY 3D-13_FILTERED 13C-EDITED NOESY 2D-13C-FILTERED NOESY 25 mM 5.1 1 atm 313 K THE COMPLEX WAS DETERMINED USING A TOTAL OF 905 NOE DISTANCE RESTRAINTS (146 INTRA RESIDUE, 203 SEQUENTIAL, 232 MEDIUM RANGE, 237 LONG-RANGE AND 87 INTERMOLECULAR), 24 HYDROGEN BOND RESTRAINTS, 139 DIHEDRAL ANGLE RESTRAINTS (72 PHI, 44 PSI AND 23 CHI-1). THE BEST 20 CONFORMERS (OF 100) HAD NO DISTANCE VIOLATIONS GREATER THAN 0.11A AND NO DIHEDRAL ANGLE VIOLATIONS GREATER THAN 1.5 DEGREES. RMSD FROM EXPERIMENTAL DISTANCE RESTRAINTS WAS 0.0049+/-0.0008. THE MEAN BACKBONE RMSD FROM THE MEAN STRUCTURE WAS 0.35 +/- 0.06 A FOR N, CA AND C ATOMS OF RESIDUES 3-26, 42-63 of IGF-I AND RESIDUES 3-15 OF THE PEPTIDE. 82% (17%) OF RESIDUES WERE IN THE MOST FAVOURED (ALLOWED) REGION OF PHI/PSI SPACE; NO RESIDUES WERE CONSISTENTLY IN THE DISALLOWED REGION. TORSION ANGLE DYNAMICS, SIMULATED ANNEALING 1 closest to the average, fewest violations 1.4 MM IGF-I (15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE 1.4 MM IGF-I (13C,15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE 1.4 MM IGF-I (13C,15N), 2.0 MM PEPTIDE, 25 MM SODIUM ACETATE D2O ACCELRYS refinement CNS 2000.1 ACCELRYS structure solution XwinNMR 3.1 ACCELRYS structure solution Felix 98 600 Bruker DRX 800 Bruker DRX GLY 1 n 1 GLY 1 A PRO 2 n 2 PRO 2 A GLU 3 n 3 GLU 3 A THR 4 n 4 THR 4 A LEU 5 n 5 LEU 5 A CYS 6 n 6 CYS 6 A GLY 7 n 7 GLY 7 A ALA 8 n 8 ALA 8 A GLU 9 n 9 GLU 9 A LEU 10 n 10 LEU 10 A VAL 11 n 11 VAL 11 A ASP 12 n 12 ASP 12 A ALA 13 n 13 ALA 13 A LEU 14 n 14 LEU 14 A GLN 15 n 15 GLN 15 A PHE 16 n 16 PHE 16 A VAL 17 n 17 VAL 17 A CYS 18 n 18 CYS 18 A GLY 19 n 19 GLY 19 A ASP 20 n 20 ASP 20 A ARG 21 n 21 ARG 21 A GLY 22 n 22 GLY 22 A PHE 23 n 23 PHE 23 A TYR 24 n 24 TYR 24 A PHE 25 n 25 PHE 25 A ASN 26 n 26 ASN 26 A LYS 27 n 27 LYS 27 A PRO 28 n 28 PRO 28 A THR 29 n 29 THR 29 A GLY 30 n 30 GLY 30 A TYR 31 n 31 TYR 31 A GLY 32 n 32 GLY 32 A SER 33 n 33 SER 33 A SER 34 n 34 SER 34 A SER 35 n 35 SER 35 A ARG 36 n 36 ARG 36 A ARG 37 n 37 ARG 37 A ALA 38 n 38 ALA 38 A PRO 39 n 39 PRO 39 A GLN 40 n 40 GLN 40 A THR 41 n 41 THR 41 A GLY 42 n 42 GLY 42 A ILE 43 n 43 ILE 43 A VAL 44 n 44 VAL 44 A ASP 45 n 45 ASP 45 A GLU 46 n 46 GLU 46 A CYS 47 n 47 CYS 47 A CYS 48 n 48 CYS 48 A PHE 49 n 49 PHE 49 A ARG 50 n 50 ARG 50 A SER 51 n 51 SER 51 A CYS 52 n 52 CYS 52 A ASP 53 n 53 ASP 53 A LEU 54 n 54 LEU 54 A ARG 55 n 55 ARG 55 A ARG 56 n 56 ARG 56 A LEU 57 n 57 LEU 57 A GLU 58 n 58 GLU 58 A MET 59 n 59 MET 59 A TYR 60 n 60 TYR 60 A CYS 61 n 61 CYS 61 A ALA 62 n 62 ALA 62 A PRO 63 n 63 PRO 63 A LEU 64 n 64 LEU 64 A LYS 65 n 65 LYS 65 A PRO 66 n 66 PRO 66 A ALA 67 n 67 ALA 67 A LYS 68 n 68 LYS 68 A SER 69 n 69 SER 69 A ALA 70 n 70 ALA 70 A ARG 101 n 1 ARG 101 B ASN 102 n 2 ASN 102 B CYS 103 n 3 CYS 103 B PHE 104 n 4 PHE 104 B GLU 105 n 5 GLU 105 B SER 106 n 6 SER 106 B VAL 107 n 7 VAL 107 B ALA 108 n 8 ALA 108 B ALA 109 n 9 ALA 109 B LEU 110 n 10 LEU 110 B ARG 111 n 11 ARG 111 B ARG 112 n 12 ARG 112 B CYS 113 n 13 CYS 113 B MET 114 n 14 MET 114 B TYR 115 n 15 TYR 115 B GLY 116 n 16 GLY 116 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A THR 29 -151.29 -47.15 1 A SER 33 -150.06 -48.76 1 A CYS 52 -105.49 -163.05 1 A LEU 64 -58.34 170.95 1 A PRO 66 -69.85 -169.18 2 A PRO 2 -72.90 -168.80 2 A THR 29 -172.58 -46.65 2 A SER 34 -157.80 -56.39 2 A THR 41 -177.56 127.77 2 A LEU 64 -58.16 -179.73 2 A ALA 67 -156.45 -68.00 2 B PHE 104 -97.92 36.37 3 A PHE 25 -59.23 -75.00 3 A SER 34 -94.41 -65.24 3 A ARG 36 -105.32 -68.92 3 A ARG 37 -162.92 34.73 3 A PRO 39 -73.33 -168.64 3 B PHE 104 -94.63 46.57 4 A THR 29 -164.42 32.22 4 A SER 35 -148.80 -65.54 4 A ALA 38 -168.94 -64.17 4 B PHE 104 -96.52 32.84 5 A PRO 2 -71.84 -168.71 5 A SER 34 -147.55 -63.37 5 A SER 35 -159.45 -74.83 5 A LEU 64 -59.22 176.33 5 A PRO 66 -61.47 83.21 5 A ALA 67 -175.58 -176.21 6 A ALA 67 -152.45 -51.89 6 A LYS 68 -139.25 -48.16 6 A SER 69 -158.72 32.73 6 B PHE 104 -96.04 37.89 7 A SER 34 -163.48 -65.45 7 A PRO 39 -65.74 -168.17 7 A ALA 67 -93.86 -70.99 8 A SER 35 -153.50 33.40 8 A PRO 39 -75.01 -168.83 8 B PHE 104 -98.60 32.86 9 A SER 34 -99.21 35.96 9 A ALA 38 -174.75 94.88 9 A PRO 66 -65.21 -167.80 9 B PHE 104 -97.27 32.82 10 A THR 29 -126.41 -58.08 10 A SER 35 -91.35 -64.06 10 A CYS 52 -111.77 -169.20 11 A PRO 2 -90.25 43.53 11 A THR 29 -179.20 -50.37 11 A TYR 31 -148.57 -52.64 11 A SER 34 -155.18 -70.67 11 A SER 35 -170.17 34.69 11 A ALA 38 -162.75 83.52 11 A PRO 39 -79.21 -168.46 11 A LEU 64 -59.97 178.82 11 A ALA 67 -170.89 118.93 11 B PHE 104 -97.87 35.80 12 A THR 29 -160.04 115.17 12 A ALA 38 -164.58 96.97 12 A LEU 64 -55.94 179.44 12 B PHE 104 -98.34 32.77 13 A LYS 27 -67.63 -177.23 13 A THR 29 -58.83 -75.48 13 A ARG 36 -88.21 -70.93 13 A CYS 52 -126.47 -160.47 14 A TYR 31 -82.06 -73.06 14 A SER 33 -149.30 -63.61 14 A PRO 66 -66.97 -167.99 14 A ALA 67 -81.52 -76.11 14 A SER 69 -163.13 33.54 15 A PHE 25 -57.32 -71.92 15 A SER 33 -149.95 -55.37 15 A ALA 38 -159.28 48.93 15 B PHE 104 -98.64 32.74 16 A PHE 25 -97.37 35.56 16 A ASN 26 -176.36 126.12 16 A ARG 37 -66.86 -168.84 16 A CYS 52 -123.78 -160.86 16 A ALA 67 -161.25 -53.41 16 A LYS 68 -147.41 -47.64 16 B PHE 104 -96.00 36.98 17 A THR 29 -153.40 -54.32 17 A SER 33 -149.27 -47.17 17 A ARG 36 -54.30 89.39 17 A LYS 68 -99.09 31.31 17 A SER 69 -141.53 32.95 17 B PHE 104 -97.68 33.19 18 A PRO 2 -75.61 -168.97 18 A ALA 38 -115.88 73.78 18 A THR 41 -177.60 125.10 18 A CYS 52 -123.32 -163.29 18 A LEU 64 -59.98 174.40 18 A LYS 68 -178.04 94.75 19 A SER 33 -150.03 -54.44 19 A CYS 52 -118.65 -164.47 19 A ALA 67 -165.43 32.12 19 A LYS 68 -101.93 -169.63 20 A PRO 2 -73.46 -169.08 20 A SER 35 -153.00 -64.41 20 A ARG 36 -90.56 -60.21 20 A ARG 37 -161.65 111.16 20 A THR 41 -177.60 107.48 20 A CYS 52 -117.00 -163.06 20 A LEU 64 -58.31 173.27 20 B PHE 104 -92.62 47.90 20 B TYR 115 -69.13 71.17 INSULIN-LIKE GROWTH FACTOR-I BOUND TO A PHAGE-DERIVED PEPTIDE 1 N N 2 N N A GLY 7 A GLY 7 HELX_P A CYS 18 A CYS 18 1 1 12 A GLY 19 A GLY 19 HELX_P A GLY 22 A GLY 22 5 2 4 A ILE 43 A ILE 43 HELX_P A CYS 48 A CYS 48 1 3 6 A ARG 55 A ARG 55 HELX_P A CYS 61 A CYS 61 1 4 7 B SER 106 B SER 6 HELX_P B TYR 115 B TYR 15 1 5 10 disulf 2.031 A CYS 6 A SG CYS 6 1_555 A CYS 48 A SG CYS 48 1_555 disulf 2.031 A CYS 18 A SG CYS 18 1_555 A CYS 61 A SG CYS 61 1_555 disulf 2.029 A CYS 47 A SG CYS 47 1_555 A CYS 52 A SG CYS 52 1_555 disulf 2.030 B CYS 103 B SG CYS 3 1_555 B CYS 113 B SG CYS 13 1_555 HORMONE/GROWTH FACTOR IGF-I, PEPTIDE BINDING, HIGH AFFINITY LIGAND, HORMONE-GROWTH FACTOR COMPLEX IGF1B_HUMAN UNP 1 49 P05019 GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA 1PMX PDB 2 1PMX 49 118 1PMX 1 70 P05019 A 1 1 70 101 116 1PMX 101 116 1PMX B 2 1 16